…t CoREST inhibition by TNG260 sensitizes STK11-mutant tumors to anti-PD1 treatment. TNG260, in combination with pembrolizumab, is being evaluated …
All extracted treatments
Showing 601–660 of 4,719, ordered by supporting articles. Choose a treatment to see its evidence.
Articles mentioning treatments
7,227 articles · page 231 of 603…ard and experimental therapies. Patients undergo tumor harvest, lymphodepleting chemotherapy, adoptive transfer of AGX-148 and high-dose IL-2 for one week, …
… experiments, we tested the effect of NanO2 in combination with immunotherapy (IT), chemotherapy (CTX, paclitaxel) or both IT and CTX. BALB/c…
…s) as well as by blocking lymphocyte egress with FTY720.Results Triplet therapy significantly delayed tumor progression and extended median sur…
…y mapped the TME to identify features potentially predictive of immunotherapy response. FFPE (Formalin-Fixed Paraffin-Embedded) tissue slide …
…t of CD4+ T cells following rechallenge (figure 2O).Conclusions T-FUS+αCD40 represents a novel paradigm for immunotherapy of BC-capab…
… evaluated in the MCA205 murine tumor model in combination with anti-PD-1 therapy. Comparative arms included treatment with FMT from ICI-non-resp…
…, suggesting possible synergy between HER2-targeted therapy and immune checkpoint blockade.In HER2-amplified colorectal cancer, PD-L1 expression and immun…
…ody drug conjugates to activate anti-tumor immunity and enhance immunotherapy response.Acknowledgements We gratefully acknowledge Immunomedic…
…es in solid tumors, yet limited data exist in the EMPD context. Adoptive CTL therapy, which involves the ex vivo expansion and activation of autolog…
… AML has remained largely unchanged over the last four decades. Immunotherapy is a promising therapy in many cancers including AML. T cell ex…
…on of the immune environment in ES may reveal the blockades for immunotherapy efforts and potential new pathways to be exploited in the futur…